Minimal clinically important difference in parkinson's disease as assessed in pivotal trials of pramipexole extended release

Parkinson's Disease

Volumn 2014, Issue , 2014, Pages

  Hauser, Robert A ^a   Gordon, Mark Forrest ^b   Mizuno, Yoshikuni ^c   Poewe, Werner ^d   Barone, Paolo ^e   Schapira, Anthony H ^f   Rascol, Olivier ^g   Debieuvre, Catherine ^h   Fräßdorf, Mandy ⁱ  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e UNIVERSITY OF SALERNO   (Italy)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g TOULOUSE UNIVERSITY HOSPITAL   (France)

^h BOEHRINGER INGELHEIM   (France)

ⁱ BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PRAMIPEXOLE;

ADVANCED PARKINSON DISEASE; ARTICLE; CHRONOTHERAPY; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG RELEASE; EARLY PARKINSON DISEASE; HUMAN; MAJOR CLINICAL STUDY; MINIMAL CLINICALLY IMPORTANT DIFFERENCE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PARALLEL DESIGN; PARKINSON DISEASE; PATIENT RATED GLOBAL IMPRESSION OF IMPROVEMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL MODEL; TREATMENT RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 84899556406     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.1155/2014/467131     Document Type: Article

References (11)

1. Caplan L. R., How well does "evidence-based" medicine help neurologists care for individual patients? Reviews in Neurological Diseases 2007 4 2 75 84 2-s2.0-34347331253 (Pubitemid 47016202)
2. Shulman L. M., Gruber-Baldini A. L., Anderson K. E., Fishman P. S., Reich S. G., Weiner W. J., The clinically important difference on the unified parkinson's disease rating scale. Archives of Neurology 2010 67 1 64 70 2-s2.0-74949137960 10.1001/archneurol.2009.295
3. Hauser R. A., Auinger P., On Behalf of the Parkinson Study Group, Determination of minimal clinically important change in early and advanced Parkinson's disease. Movement Disorders 2011 26 5 813 818 2-s2.0-79955101051 10.1002/mds.23638
4. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease, The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Movement Disorders 2003 18 7 738 750 2-s2.0-0042591659 10.1002/mds.10473 (Pubitemid 36939968)
5. Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health, Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims 2006 Rockville, Md, USA US Department of Health and Human Services
6. Schrag A., Sampaio C., Counsell N., Poewe W., Minimal clinically important change on the Unified Parkinson's Disease Rating Scale. Movement Disorders 2006 21 8 1200 1207 2-s2.0-33748320447 10.1002/mds.20914 (Pubitemid 44336608)
7. Rascol O., Defining a minimal clinically relevant difference for the Unified Parkinson's Rating Scale: an important but still unmet need. Movement Disorders 2006 21 8 1059 1061 2-s2.0-33748360763 10.1002/mds.20913 (Pubitemid 44336586)
8. Hauser R. A., Schapira A. H. V., Rascol O., Barone P., Mizuno Y., Salin L., Haaksma M., Juhel N., Poewe W., Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Movement Disorders 2010 25 15 2542 2549 2-s2.0-78349260064 10.1002/mds.23317
9. Poewe W., Rascol O., Barone P., Hauser R. A., Mizuno Y., Haaksma M., Salin L., Juhel N., Schapira A. H. V., Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. Neurology 2011 77 8 759 766 2-s2.0-80053014870 10.1212/WNL.0b013e31822affb0
10. Schapira A. H. V., Barone P., Hauser R. A., Mizuno Y., Rascol O., Busse M., Salin L., Juhel N., Poewe W., Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology 2011 77 8 767 774 2-s2.0-80054027550 10.1212/WNL.0b013e31822affdb
11. Parkinson Study Group, A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Archives of Neurology 2002 59 1937 1943